Boehringer Ingelheim Receives FDA Approval for HERNEXEOS® for HER2-Mutant Advanced NSCLC
Friday, February 27, 2026
Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for HERNEXEOS® (zongertinib tablets) as the first targeted therapy for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) to be used as an initial treatment option.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for around 85 per cent of all cases. It usually develops more slowly than small cell lung cancer, but many patients are diagnosed at an advanced stage when symptoms become noticeable.
HER2 (ERBB2) mutations are found in approximately 2–4 per cent of NSCLC cases and are associated with poor prognosis and a higher likelihood of brain metastases. NSCLC is the most common form of lung cancer, and many cases are diagnosed at an advanced stage. Survival outcomes remain low, highlighting the continued need for additional targeted treatment options.
HERNEXEOS eligibility is determined through comprehensive biomarker testing, including next-generation sequencing, to identify HER2 (ERBB2) mutations in patients with advanced NSCLC.
Zongertinib is an irreversible tyrosine kinase inhibitor designed to selectively target HER2 (ERBB2) mutations while sparing wild-type EGFR, with the aim of reducing related toxicities. It is administered orally once daily.
The approval applies to patients whose tumours carry HER2 tyrosine kinase domain activating mutations identified through an FDA-authorised diagnostic test.
The decision has been granted under the accelerated approval pathway, based on objective response rate and duration of response.
The company is currently enrolling patients into Beamion LUNG-2, a Phase III confirmatory trial evaluating zongertinib as a first-line treatment for advanced NSCLC with HER2 tyrosine kinase domain mutations. In addition, Beamion LUNG-3 is assessing the therapy as an adjuvant monotherapy in patients with early-stage, resectable HER2-mutant NSCLC.
Source: boehringer-ingelheim.com
